Description
Zn-c3 (also known as ZN-c3) is an investigational, oral small-molecule inhibitor of WEE1 kinase currently being evaluated in clinical trials for various advanced solid tumors, including colorectal cancer. It is being studied primarily in patients with refractory or advanced cancers, often in combination with other agents such as chemotherapy or targeted therapies. As an experimental agent, it is not yet approved for routine clinical use in CRC, and access is generally limited to clinical trial settings.
Mechanism of Action
Zn-c3 selectively inhibits WEE1, a kinase that regulates the G2/M cell cycle checkpoint and plays a critical role in DNA damage repair. By blocking WEE1, Zn-c3 forces cancer cells—particularly those with defects in other DNA damage response pathways (e.g., TP53 mutations)—to enter mitosis with unrepaired DNA damage, leading to mitotic catastrophe and cell death.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.